Suchergebnisse - "Gerogianni, Alexandra"

PubPharm (8)

1

In vitro evaluation of iron oxide nanoparticle-induced thromboinflammatory response using a combined human whole blood and endothelial cell model

enthalten in: Frontiers in immunology | 2023

von Gerogianni, A. | Bal, M. | Mohlin, C. | +5

2

Functional evaluation of complement factor I variants by immunoassays and SDS-PAGE

enthalten in: Frontiers in immunology | 2023

von Gerogianni, A. | Baas, L. | Sjöström, D. | +5

3

Complement C3b contributes to Escherichia coli-induced platelet aggregation in human whole blood

enthalten in: Frontiers in immunology | 2022

von Landsem, A. | Emblem, �. | Lau, C. | +6

4

Heme Interferes With Complement Factor I-Dependent Regulation by Enhancing Alternative Pathway Activation

enthalten in: Frontiers in immunology | 2022

von Gerogianni, A. | Dimitrov, J. | Zarantonello, A. | +9

5

Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood

enthalten in: Journal of immunology (Baltimore, Md. : 1950) | 2019

von Thomas, A. | Gerogianni, A. | McAdam, M. | +6

6

Tailoring the specificity of the type C feruloyl esterase FoFaeC from Fusarium oxysporum towards methyl sinapate by rational redesign based on small molecule docking simulations

enthalten in: PloS one | 2018

von Antonopoulou, I. | Hunt, C. | Cerullo, G. | +5

7

Symptom improvement in lung cancer patients treated with erlotinib : quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2006

von Bezjak, A. | Tu, D. | Seymour, L. | +16

ErratumIn: J Clin Oncol. 2007 Jan 1;25(1):167

8

Original Reports - LUNG CANCER - Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

enthalten in: Journal of clinical oncology / Englische Ausgabe | 2006

von Bezjak, A. | Tu, D. | Seymour, L. | +15

1
[1]